Bristol Myers Squibb Stock - Director exercises options in fresh Form 4

Bristol Myers Squibb stock draws attention after director Julia A. Haller exercised stock options for more than 20,000 shares, as disclosed in a recent Form 4 filing. On Wednesday, the broader focus also stays on the group’s operations and strategy.

Edited by ad hoc news Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 19:12 UTC. Details in the imprint.

Bristol Myers Squibb (US0897961004) reported fresh insider activity this week. According to a Form 4 referenced by specialist portal StockTitan, director Julia A. Haller exercised stock options for 20,460 shares at a price of $53.76 per share.

Details of the insider transaction

StockTitan summarizes that Haller’s options were exercised on 06/15/2026, in a cash transaction, and that she chose to retain all 20,460 acquired shares rather than selling them immediately. The exercise price of $53.76 implies a total consideration of roughly $1.1 million.

Following the exercise, Haller directly holds 34,079 Bristol Myers Squibb shares, and the option grant covering these 20,460 shares is now fully exercised. The filing classifies the instrument as an “Option (right to buy)” for common stock.

Operations and strategic backdrop

Bristol Myers Squibb positions itself as a global biopharmaceutical group with a portfolio spanning oncology, hematology, cardiovascular and immunology therapies, including key drugs such as Eliquis and Opdivo, alongside newer launches in its pipeline. Management continues to emphasize innovation and business development to offset patent expiries.

Recent investor commentary has focused on the company’s sizable dividend yield and cash generation, which underpin its ability to fund research and development, acquisitions and shareholder returns. According to a recent analysis, the dividend yield is well above the broader market and seen as reasonably supported by underlying cash flows.

How the company makes money

The core of Bristol Myers Squibb’s business model is the discovery, development and commercialization of prescription medicines, with blockbuster revenue contributions from cardiovascular drug Eliquis, cancer immunotherapy Opdivo and other specialty therapies across hematology and immunology.

Where the stock trades today

Shares of Bristol Myers Squibb (US0897961004) trade on the New York Stock Exchange under the ticker BMY at $57.13 as of 06/12/2026, 16:00 ET.

Key facts on Bristol Myers Squibb stock

• Company: Bristol-Myers Squibb Company
• ISIN: US0897961004
• WKN: 850501
• Ticker: BMY
• Venue: NYSE
• Price (as of 06/12/2026, 16:00 ET): 57.13 USD
• Market cap: 116,000,000,000 USD (as of 06/12/2026)
• Sector / Industry: Health Care / Pharmaceuticals
• Index membership: S&P 500
• Next earnings date: not officially scheduled

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.